Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75865
UPID:
TPC6A_HUMAN
Alternative names:
-
Alternative UPACC:
O75865; K7ERB1; K7ERQ4; Q9BQ45; Q9P092
Background:
Trafficking protein particle complex subunit 6A plays a crucial role in vesicular transport, essential for the biogenesis of melanosomes. This protein is pivotal in the cellular processes that ensure the proper distribution and function of melanosomes, organelles responsible for pigment synthesis and storage in melanocytes.
Therapeutic significance:
Understanding the role of Trafficking protein particle complex subunit 6A could open doors to potential therapeutic strategies. Its involvement in melanosome biogenesis highlights its potential impact on conditions related to pigment synthesis and distribution, offering a promising avenue for research into skin and pigmentary disorders.